Human Papillomavirus and Oropharyngeal Cancer

Home Forums Oral Diagnosis & Medicine Human Papillomavirus and Oropharyngeal Cancer

Welcome Dear Guest

To create a new topic please register on the forums. For help contact : discussdentistry@hotmail.com

Currently, there are 0 users and 1 guest visiting this topic.
Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #12046
    sushantpatel_doc
    Offline
    Registered On: 30/11/2009
    Topics: 510
    Replies: 666
    Has thanked: 0 times
    Been thanked: 0 times

    According to numerous reports the incidence for oropharyngeal cancer is increasing, and human papilloma­virus (HPV) is a risk factor. However, few studies have investigated the specific subsites of the oropharynx. Following their previous research on tonsillar cancer, Attner, et al assessed the increase in the incidence of base of tongue cancer and the prevalence of HPV in this disease. The study took place between 1998 and 2007 and involved 109 patients who were diagnosed for base of tongue cancer in Stockholm county, Sweden. The re­searchers obtained 95 paraffin-embedded diagnostic tumor biopsies from patients and tested them for HPV. Expression of HPV-16 RNA was analyzed to confirm E6 and/or E7 expression. According to incidence data from the Swedish Cancer Registry, an overall increase in the incidence of base of tongue cancer from 2005 to 2007 were found to be 0.15/100,000 person-years during 1970 to 1974 to 0.47/100,000 person-years. The prevalence of HPV in base of tongue cancer in Stockholm county increased from 58% during 1998 to 2001 to 84% during 2004 to 2007 (P < .05). In the HPV-positive tumors, HPV-16 dominated (86%) but HPV33 was detected in as many as 10%. E6 and/or E7 RNA were found in 85% of the samples tested. The incidence of base of tongue cancer, as well as the proportion of HPV-positive tumors, has increased in Sweden during the study period. This suggests that HPV may contribute to this increase.

    #17232
    Anonymous

    * The new human papillomavirus vaccine (HPV) is recommended in a three-dose schedule with the second and third doses administered two and six months after the first dose. Routine vaccination with HPV is recommended for females aged 11-12 years; the vaccination series can be started in females as young as age 9 years; and a catch-up vaccination is recommended for females aged 13-26 years who have not been vaccinated previously or who have not completed the full vaccine series.

    * The main change to the format of the schedule is the division of the recommendation into two schedules: one schedule for persons aged 0-6 years) and another for persons aged 7-18 years. Rota, HPV, and varicella vaccines are incorporated in the catch-up immunization schedule.

Viewing 2 posts - 1 through 2 (of 2 total)
  • You must be logged in to reply to this topic.